Biogen Idec 3Q Revenues: $1.4 billion (+6%) 3Q Earnings: $398.4 million (+13%) YTD Revenues: $4.1 billion (+10%) YTD Earnings: $1.1 billion (+16%) Comments: Avonex sales were $736 million (+8%). Tysabri sales were $275 million (-1%). Rituxan revenues from an unconsolidated joint business arrangement were $288 million (+8%). Global in-market sales of Tysabri were $404 million (+3%), including $230 million in the U.S. Revenues from other products were $28 million, compared to $17 million in 3...